Precipio Gets Extension to Meet Nasdaq Listing Requirement

Sep 28, 2018

|

NEW YORK (360Dx) – Precipio said on Thursday that Nasdaq has granted it a 180-day extension to meet a requirement to remain listed on the exchange.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

Breakthrough Prize Winners Announced

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

Misuse of Genetic Research

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Not Quite the Ivy League Gene

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

This Week in Nature

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Featured White Papers

Sampling for Optimal cfDNA Extraction

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Point of Care Testing Using Smartphone Diagnostic Readers - Download FAQ Guide

Discovering Neuronal Cell Types

Oct

25

Featured Webinar

A Comprehensive Strategy for Evaluating NGS Liquid Biopsy and Tumor Tissue Assays

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate NGS oncology assays for genomic tumor profiling of plasma and tissue samples.

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov

07

Featured Webinar

Implementation of a Comprehensive NGS Oncology Panel including MSI and TMB Signatures

This webinar will provide a first-hand look at how a leading pathology lab implemented a next-generation sequencing panel to capture comprehensive molecular tumor profiles.

Nov

27

Featured Webinar

Defining a Multi-Omics Target Discovery Framework for High-Risk Cancers

While next-generation sequencing (NGS) has driven recent advances in precision oncology research, it often falls short when identifying the molecular mechanisms underlying many malignancies. As a result, alternative NGS-based approaches are needed to identify oncogenic drivers and potential drug targets.

Main menu